What Vaccines Teach Us About Dengue Immunity
The Journal of Infectious Diseases · 17.11.2026
DOI: 10.1093/infdis/jiag553 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 17.11.2026. Verfasst von Scott B Halstead. Beteiligte Einrichtung: Dengue Vaccine Consultant, Westwood, Massachusetts, USA. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
During World War II, 4 dengue viruses emerged in Southeast Asia. They then circulated in tropical countries around the globe. The high-level incidence of dengue virus infections was attributed to an unusual immunologic phenomenon: antibody-dependent enhancement of dengue infection. This resulted in the occurrence of severe, sometimes fatal, dengue vascular permeability syndrome. In the absence of effective large-scale control of the mosquito vector of dengue, Aedes aegypti, health experts turned to vaccines. Sanofi-Pasteur produced Dengvaxia, a live attenuated yellow fever vaccine–dengue virus chimera. Upon inoculation, the products of the pre-M and E genes of the 4 dengue viruses were replicated and released. In 2016, the government of the Philippines administered Dengvaxia to children at scale. Separately, in children of Cebu, some of the authors of this research report designed and conducted an independent efficacy study of Dengvaxia [1, 2]. This is a seroconversion study of 2996 children aged 9 to 14 years. Of them, 60% were vaccinated and 40% were controls. Research was directed to individuals immune to a single dengue virus. These children were at risk of acquiring clinically severe second heterotypic dengue infections. In the vaccine arm were 138 children with monotypic immunity, who received a single dose of the Sanofi yellow fever–dengue chimeric vaccine. Another 76 children with monotypic dengue immunity served as unvaccinated controls. Some of these same authors, studying vaccinated nonimmune samples, found the DENV 4 component of Dengvaxia to be immunodominant [3, 4]. In the present study, when the DENV 4 monotypic immune group was given Dengvaxia, it suppressed secondary-type antibody responses at a high frequency (11/18, 61%). That is, the vaccine did not “take.” These suppressed antibody responses were not observed in the DENV 1, 2, and 3 monotypic dengue-immune groups given Dengvaxi. All of the children had broad secondary-type antibody responses. It can be concluded that a single dose of Dengvaxia boosted antibody responses poorly among children with DENV 4 immunity, resulting in individuals continuing to be at risk to wild type secondary dengue virus infections. What happened? In this study, individuals with immunity acquired from a wild type DENV 4 infection who were given Dengvaxia suppressed secondary dengue antibody responses. In contrast, Dengvaxia given to those with DENV 1, 2, or 3 monotypic immunity resulted in normal secondary serotype cross-neutralizing antibody responses. This is telling us something important about the preemptive power of DENV 4 antigens in Dengvaxia to suppress the immune system. Is it possible that this phenomenon contributed to suppress the efficacy of Dengvaxia in the Philippines? Efficacy in the extensive Dengvaxia clinical trials had been based mostly on children receiving 3 doses of vaccine. The broad suppression of antibody responses to Dengvaxia in DENV 4 immune samples is an interesting immunologic puzzle. Thus far, there are no reports that Takeda's Qdenga or Butantan's DV given to individuals with monotypic dengue immunity had experienced suppressed secondary-type antibody responses. These vaccines differ from Dengvaxia. Each contains at least 1 live attenuated virus. Qdenga contains an attenuated dengue virus, DENV 2, while Butantan DV contains live attenuated DENV 1, 3, and 4. Did live attenuated viruses, when given to individuals with monotypic immunity, contribute to a robust immune response? With Dengvaxia off the market, this puzzle may not be solved. In the context of constructing a competent dengue vaccine, it is appropriate to alert readers to important changes to our understanding of the pathogenesis of dengue virus infections. These evolve from the discovery that dengue nonstructural protein type 1s (NS1s) are endothelial toxins. Circulation of NS1s during acute antibody-enhanced dengue infections contributes to the acute, rapid vascular permeability that causes many dengue deaths [5, 6]. NS1 molecules have also been found to modulate fibrinolysis, contributing to hemorrhaging, another pillar of the pathogenesis of dengue hemorrhagic fever [7]. Despite insistent global demands that the transmission of dengue viruses be halted, the full elimination of A aegypti is seemingly beyond reach. More than ever, a competent vaccine is needed. My strong bias is that achieving full, sustained protection requires an effective pan-dengue vaccine containing structural and nonstructural antigens capable of raising effective antibodies and cell-mediated immunity [8]. Might such a vaccine be lurking in the shadows [9]? Financial support. No financial support was received for this work.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dengue Vaccine Consultant, Westwood, Massachusetts, USA.
ORCID-Profile: Scott B Halstead
Zitieren
APA
Halstead, S. B. (2026). What Vaccines Teach Us About Dengue Immunity. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag553
Vancouver
Halstead SB. What Vaccines Teach Us About Dengue Immunity. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag553
BibTeX
@article{Halstead2026,
author = {Halstead, Scott B},
title = {What Vaccines Teach Us About Dengue Immunity},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag553}
}
EUVIMED